INTRODUCTION
============

Chronic obstructive pulmonary disease (COPD), a complex age-related disease, has two components: chronic bronchitis, characterized by productive cough, and emphysema, demonstrated by destruction of the lung parenchyma ([@b2-ksmcb-42-333]; [@b32-ksmcb-42-333]; [@b37-ksmcb-42-333]; [@b56-ksmcb-42-333]). COPD patients also suffer from shortness of breath due to chronic airway obstruction and inflammation ([@b12-ksmcb-42-333]; [@b56-ksmcb-42-333]). COPD is generally diagnosed by chronic and irreparable impairment of lung airflow ([@b1-ksmcb-42-333]; [@b5-ksmcb-42-333]; [@b8-ksmcb-42-333]; [@b56-ksmcb-42-333]). The most prominent cause of COPD is cigarette smoking (CS), although this factor is not the only cause of the disease, and not all smokers have the disease ([@b7-ksmcb-42-333]; [@b21-ksmcb-42-333]; [@b31-ksmcb-42-333]; [@b33-ksmcb-42-333]; [@b49-ksmcb-42-333]; [@b52-ksmcb-42-333]).

Several recent studies have shown that genetic factors contribute to COPD ([@b3-ksmcb-42-333]; [@b13-ksmcb-42-333]; [@b20-ksmcb-42-333]; [@b41-ksmcb-42-333]; [@b42-ksmcb-42-333]). For instance, loss-of-function mutation of α1-antitrypsin is a well-known genetic risk factor, although it is responsible for only 1--5% of COPD patients ([@b45-ksmcb-42-333]; [@b48-ksmcb-42-333]). In addition, with the recent success of genome-wide association studies (GWAS), the list of COPD-associated genes is expanding rapidly, including FAM13A, HHIP, IREB2, RAB4B, EGLN2, MIA, CYP2A6 ([@b14-ksmcb-42-333]; [@b16-ksmcb-42-333]; [@b23-ksmcb-42-333]). Note that many COPD-associated single nucleotide polymorphisms (SNPs) are located in noncoding regions such as intergenic and intronic regions ([@b4-ksmcb-42-333]; [@b39-ksmcb-42-333]) rather than in protein-coding regions, which is also the case for other disease-associated SNPs. These noncoding but disease-associated SNPs may contribute to the altered regulation of gene expression, splicing, and epigenetic modifications.

Interestingly, CS can perturb gene expression by affecting various epigenetic markers including DNA methylation and chromatin modification ([@b6-ksmcb-42-333]; [@b25-ksmcb-42-333]; [@b29-ksmcb-42-333]). A variety of epigenetic machineries for regulating downstream gene expression are known to be altered in COPD ([@b27-ksmcb-42-333]; [@b43-ksmcb-42-333]). All these studies consistently indicate that both genetic and epigenetic alterations are important in the etiology of COPD. However, the mechanism by which these genes and their genetic mutations mediate the pathogenesis of the disease remains to be elucidated.

Meanwhile, an understanding of the perturbations in gene expression in various diseases will potentially contribute to the identification of molecular targets to develop new therapeutic drugs or prognostic modalities. Transcriptome studies using either microarrays or RNA-Seq approaches have been employed for those purposes in COPD as well ([@b10-ksmcb-42-333]; [@b23-ksmcb-42-333]; [@b38-ksmcb-42-333]; [@b47-ksmcb-42-333]; [@b57-ksmcb-42-333]). For instance, according to [@b57-ksmcb-42-333], extracellular matrix (ECM) and apoptosis genes are upregulated, whereas genes involved in anti-inflammatory functions are down-regulated in a microarray of 48 human lung samples, including normal tissues and samples from patients with various stages of COPD ranging from GOLD (Global Initiative for Chronic Obstructive Lung Diseases) stage 0 to GOLD stage 3. In addition, several other genes involved in inflammatory responses, including cytokines and chemokines, and genes involved in oxidative stress responses are associated with COPD progression ([@b10-ksmcb-42-333]; [@b23-ksmcb-42-333]; [@b38-ksmcb-42-333]; [@b47-ksmcb-42-333]).

However, alterations in gene expression are notably heterogeneous among studies with different designs using different cell types ([@b34-ksmcb-42-333]), which is not surprising because 12 different cell types constitute the whole lung tissue ([@b57-ksmcb-42-333]). Moreover, most subjects with COPD were also diagnosed with lung cancers, which was the reason for undergoing lung resection, and thus the DEG results cannot be as easily interpreted as the genes that are altered by COPD alone ([@b57-ksmcb-42-333]). As shown in the study by [@b46-ksmcb-42-333], gene expressions in normal airway epithelial cells derived from patients with lung cancers differ in a cancer-specific manner.

In the present study, we thus attempt to avoid complexities in estimating DEGs associated with COPD (i.e., COPD-DEGs) driven by different cancer backgrounds co-occurring with COPD or by likely misclassified patient samples named group 'I', basically by revisiting the previous study published by [@b23-ksmcb-42-333]. In addition, we integrate the COPD-DEGs with various multi-omics data, revealing novel insights relevant to COPD, which may ultimately contribute to improving our understanding of the molecular etiology of COPD or to identifying molecular targets for the development of a novel diagnostic or prognostic strategy.

MATERIALS AND METHODS
=====================

Data download
-------------

For the present study, we obtained the RNA-Seq data produced from COPD patients with lung cancers from [@b23-ksmcb-42-333] (<https://www.ncbi.nlm.nih.gov/geo/>, GSE57148). Refer to [@b23-ksmcb-42-333] for a detailed procedure describing the process to align and map the raw FASTQ files to the reference genome (GRCh37/hg19) and to generate FPKM values for all samples using Tophat and Cufflinks ([@b53-ksmcb-42-333]; [@b55-ksmcb-42-333]; [@b54-ksmcb-42-333]).

DEG analysis
------------

FPKM values downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>, GSE57148) were converted into log~2~ (FPKM + 1) values, and quantile normalization was carried out for the expression values using R. Subsequently, after assessing the normality using the Shapiro-Wilk test, we applied two different *t* -tests to identify DEGs, depending on whether the FPKMs exhibited a normal distribution: a two-sample *t* -test was applied to the data with a normal distribution, whereas the non-parametric Wilcoxon Rank-Sum test was used for the data that did not display normal distribution. We referenced the method used by several previous studies ([@b28-ksmcb-42-333]; [@b35-ksmcb-42-333]; Park et al., 2016; [@b60-ksmcb-42-333]). Two cutoff values were selected to identify DEGs; Q \< 0.01 and an absolute fold change (FC) estimated by (COPD mean FPKM/normal mean FPKM) ≥ 1.5 for all samples, and Q \< 0.01 and \|FC\| ≥ 2 for the samples excluding group 'I'. In addition, we further classified the 189 samples into three different groups -- normal ('N'), intermediate ('I'), and COPD ('C') -- using *k*-means clustering ([@b15-ksmcb-42-333]).

Subgrouping of the COPD samples
-------------------------------

The 189 patient samples in the GSE57148, comprising 91 samples labeled 'normal' and 98 samples labeled 'COPD', were further divided into COPD coupled with adenocarcinoma (AC-COPD; 58 normal versus 36 COPD) and COPD coupled with squamous cell carcinoma (SC-COPD; 33 normal versus 62 COPD). Detailed clinical information on the sex, age, FEV1/FVC ratio, and cancer types of the samples was retrieved from [@b23-ksmcb-42-333] and is provided as [Supplementary Table S1](#s2-ksmcb-42-333){ref-type="supplementary-material"} in the paper; all samples were collected from male patients.

Obtaining COPD-related miRNAs
-----------------------------

A total of 45 differentially expressed miRNAs (DE-miRNAs) detected in COPD were obtained from [@b21-ksmcb-42-333]. Information about miRNAs and their target mRNAs was obtained from miRTarBase (ver. 7.0, <http://mirtarbase.mbc.nctu.edu.tw>)([@b11-ksmcb-42-333]), where a total of 2,599 miRNAs and their target genes are deposited. Forty-three DE-miRNAs, missing 2 miRNAs, were linked to a total of 4,786 mRNAs.

Obtaining COPD-related genes and eQTLs
--------------------------------------

A total of 910 previously known COPD-associated genes were obtained from the gene-disease association (GDA) database of DisGeNET (ver. 5.0, <http://www.disgenet.org/>) (Piñero et al., 2016). Lung expression quantitative trait locus (eQTL) data were obtained from GTEx Portal (ver. 7, <https://www.gtexportal.org/>)([@b30-ksmcb-42-333]), where a total of 25,283 eQTL-gene interactions with 24,653 SNPs and 25,243 genes were found. Among them, we used 11,297 eQTL genes that were shown to have significant interactions with gene expression at an FDR-adjusted *p*-value (Q) \< 0.05.

Data analysis
-------------

All statistical tests and their related diagrams were implemented with R (ver. 3.5.0, <https://cran.r-project.org/doc/manuals/r-release/R-intro.pdf>) and Bioconductor packages (ver. 3.7)([@b18-ksmcb-42-333]). *k*-means clustering was also performed with the same R package by setting *k* = 3. HaploReg (ver. 4.1, <https://pubs.broadinstitute.org/mammals/haploreg>)([@b58-ksmcb-42-333]) was used to annotate SNPs in the context of regulatory regions such as transcription factor binding sites (TFBSs), enhancers, promoters, and DNaseI hypersensitivity sites (DHSs). Gene Ontology (GO) analysis was conducted using the DAVID tool (ver. 6.8; <https://david.ncifcrf.gov/>)([@b17-ksmcb-42-333]). A gene set enrichment analysis (GSEA) was performed using the GSEA package (ver. 3.0)([@b50-ksmcb-42-333]); we used 'biological process' (bp) of curated gene sets c5, which contain gene sets collected from the GO database (MSigDB, ver. 6.2)([@b50-ksmcb-42-333]). The 'ReactomeFI' Cytoscape plugin was used to investigate the functional interactions among the DEGs we identified. In addition, one of the 'ReactomeFI' pull-down menu items, 'cluster FI Network' ([@b59-ksmcb-42-333]), was used to identify GO terms for the clustered modules. Other batch jobs were performed with custom-built Python scripts (ver. 3.6.0).

Quantitative real-time PCR (qRT-PCR) analysis
---------------------------------------------

Total RNA was extracted from two types of mouse COPD models, i.e., five mice from the elastase-induced model ([@b51-ksmcb-42-333]) and three mice from the smoking-induced model ([@b9-ksmcb-42-333]); please refer to previous studies to find detailed protocols for constructing mouse COPD model systems ([@b9-ksmcb-42-333]; [@b19-ksmcb-42-333]; [@b24-ksmcb-42-333]; [@b51-ksmcb-42-333]). Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Germany) according to the manufacturer's instructions, and the concentration was quantified with an Epoch Microplate Spectrophotometer (Biotek Instruments, Inc.). The quality of total RNAs was then tested by measuring the ratio of absorbance at 260 nm and 280 nm. Reverse transcription was conducted using the TOPscriptδ RT DryMIX kit (Enzynomics); for PCR, 1 μl of synthesized cDNA was used with AccuPower PCR pre-MIX (Bioneer). Quantitative real-time PCR (qPCR) was performed to quantify the mRNA expression of candidate genes using the ABI Step One Plus System Instrument (Applied Biosystems). The qPCRs were performed according to the manufacturer's instructions with TOPrealδ qPCR 2X PreMIX SYBR Green with high ROX (Enzynomics) in a Microamp fast 96-well reaction plate. Levels of relative gene expression were normalized to GAPDH expression. The primer sequences are provided in [Supplementary Table S2](#s3-ksmcb-42-333){ref-type="supplementary-material"}.

RESULTS
=======

Overall schematic of the workflow
---------------------------------

We collected RNA-Seq data from a total of 189 samples from the Gene Expression Omnibus (GEO) database (see Methods) to revisit the previous findings ([@b23-ksmcb-42-333]) regarding COPD-associated gene expression signatures. As described in the original paper, the samples were all derived from either adenocarcinoma (AC) or squamous cell carcinoma (SC) of the lungs, regardless of whether they were labeled normal or COPD. Therefore, the terms 'normal' and 'COPD' here refer to lung cancer patients without COPD and lung cancer patients with COPD, respectively. We thus decided to classify COPD patients into two groups by the lung cancer types from which they suffered simultaneously, i.e., COPD patients with adenocarcinoma (AC-COPD) and COPD patients with squamous cell carcinoma (SC-COPD)([Fig. 1](#f1-ksmcb-42-333){ref-type="fig"}). Accordingly, the samples from AC and SC patients without COPD were named 'AC-normal' and 'SC-normal', respectively.

Consistent with the study by [@b23-ksmcb-42-333], patients with COPD tended to be older, to have more pack-years of CS, and to have a significantly lower FEV1/FVC ratio than individuals without COPD ([Supplementary Fig. S1](#s1-ksmcb-42-333){ref-type="supplementary-material"}). However, a significantly greater proportion of patients with COPD presented SC than AC; in contrast, a greater proportion of normal samples presented AC than SC ([Supplementary Fig. S1](#s1-ksmcb-42-333){ref-type="supplementary-material"}). The biased distribution of patients with COPD between the AC and SC groups might skew the results of the DEG estimation; specifically, the DEGs between normal controls and patients with COPD might be skewed by DEGs between AC and SC. Therefore, in the present work, we decided to analyze COPD-associated gene expression signatures separately for AC and SC; the overall schematic of the present work is depicted in [Fig. 1](#f1-ksmcb-42-333){ref-type="fig"}.

Existence of an intermediate group of patients with ambiguous expression patterns
---------------------------------------------------------------------------------

We separately identified DEGs for the two COPD groups classified by the two cancer types, AC and SC, using cutoff values of Q \< 0.01 and \|fold change (FC)\| ≥ 1.5 (see Methods). As a result, 150 DEGs were identified between 58 AC-normal and 36 AC-COPD samples (named AC-DEGs), and 58 DEGs were identified between 33 SC-normal and 62 SC-COPD samples (named SC-DEGs).

We conducted heatmap analysis accompanied by unsupervised hierarchical clustering for AC and SC to investigate whether these DEGs demarcated the normal and COPD samples ([Figs. 2A and 2D](#f2-ksmcb-42-333){ref-type="fig"}). The classification of samples by the DEGs was not perfect in either cancer types (i.e., some normal samples are clustered in an intermingled way with some COPD samples, and vice versa), leading to the recognition of a third group of patient samples, separate from normal and COPD.

We thus performed *k*-means clustering of samples by setting a parameter *k* = 3 for AC and SC and integrated the resulting sample clusters by principal component analysis (PCA). The third group, the intermediate group, which was classified as neither normal nor COPD, is represented by gray dots in the PCA graph ([Fig. 2B and 2E](#f2-ksmcb-42-333){ref-type="fig"}). For AC and SC, the samples were thus reclassified into three groups, i.e., group 'N' (normal), group 'I' (intermediate), and group 'C' (COPD); see Methods.

Interestingly, the median FEV1/FVC ratio of group 'I' was approximately equivalent to group 'N', although the ratio ranged widely from less than 50% (clinical COPD) to greater than 80% (clinically normal) for both AC and SC ([Figs. 2C and 2F](#f2-ksmcb-42-333){ref-type="fig"}). Based on this result, group 'I' may contain misclassified patient samples, although they had been clinically diagnosed with or without COPD.

Defining reliable DEGs for deciphering the molecular etiology of COPD NC-DEGs
-----------------------------------------------------------------------------

After establishing a third group of patients, group 'I', we decided to re-identify the three sets of DEGs to determine how the gene expression patterns of the patients in group 'I' e differed. We defined NC-DEGs, NI-DEGs, IC-DEGs by comparing gene expression between groups 'N' and 'C', 'N' and 'I', and 'I' and 'C', respectively. Several statistical cutoff values for defining the three sets of DEGs were tested, from which we found that very few NI- and IC-DEGs remained when Q \< 0.01 and \| FC\| ≥ 2 were applied. However, 237 NC-DEGs still remained as DEGs at those stringent cutoffs ([Supplementary Table S3](#s3-ksmcb-42-333){ref-type="supplementary-material"}). The fact that very few DEGs appeared between groups 'N' and 'I', and groups 'I' and 'C' suggests that estimating COPD-DEGs by including group 'I' in the original labels as either normal or COPD renders the DEGs to be less reliable markers for demarcating samples. In other words, NC-DEGs, rather than NI-DEGs and IC-DEGs, are more confident gene sets to investigate the molecular etiology of COPD, which is why we chose to use NC-DEGs for a reliable identification of COPD-DEGs.

Next, we tried to obtain common COPD-DEGs between AC-COPD and SC-COPD groups by collecting common NC-DEGs identified based on the intersection between the NC-DEG sets of AC and SC. As shown in [Fig. 3](#f3-ksmcb-42-333){ref-type="fig"}, 237 common NC-DEGs (the bottom panel), including 131 upregulated and 106 downregulated genes, differentiated COPD from normal samples without ambiguity for both AC (the top left panel) and SC (the top right panel) using a heatmap accompanied by unsupervised hierarchical clustering. Notably, samples from group 'I' were excluded from this analysis of both AC and SC.

Common DEGs for both AC and SC reveal well-known COPD-related genes
-------------------------------------------------------------------

The intersection between NC-DEGs for AC and SC produced two additional groups of gene sets, 'AC-specific' (316 genes) and 'SC-specific' (62 genes), as well as the common NC-DEGs ([Fig. 4](#f4-ksmcb-42-333){ref-type="fig"}). Moreover, according to the direction of the changes in expression (up- or downregulation), these three categories of NC-DEGs were divided into six categories: 'Common-up' (131 genes), 'Common-down' (106 genes), 'AC-specific-up' (140 genes), 'AC-specific-down' (176 genes), 'SC-specific-up' (29 genes), and 'SC-specific-down' (33 genes)([Fig. 4A](#f4-ksmcb-42-333){ref-type="fig"}).

We performed a GO analysis of each of the 6 categories of DEGs, confirming several previously well-known COPD-related genes in the 'common' category. For instance, GO functions such as 'inflammatory response', 'cell adhesion', and 'ECM' were significantly enriched in the 'Common-up' category, whereas mitochondria-related functions were significantly enriched in the 'Common-down' category ([Fig. 4A](#f4-ksmcb-42-333){ref-type="fig"}). Interestingly, all these functional GO terms were completely consistent with the findings from recent reviews aiming to decipher the molecular pathology of COPD ([@b10-ksmcb-42-333]; [@b57-ksmcb-42-333]). Similar GO functional terms appeared in both AC-specific and SC-specific categories, although the numbers of genes associated with specific functional terms differed, suggesting that genes involved in molecular pathways associated with COPD etiology were commonly altered as well. Notably, however, inflammatory and apoptosis genes were prominent functional terms for the AC-specific category, but not the SC-specific category, whereas cell proliferation genes showed the opposite trend ([Fig. 4A](#f4-ksmcb-42-333){ref-type="fig"}). We postulate that this difference in functional GO terms exists because the etiology of COPD in patients with AC and SC is not identical due to different genetic and epigenetic conditions associated with each cancer type. Notably, the GSEA generally provided the same interpretation as the GO analysis (data not shown).

We then created a functional interaction network with the ReactomeFI Cytoscape plugin (see the Methods) using these 615 NC-DEGs assigned into the six different categories ([Fig. 4B](#f4-ksmcb-42-333){ref-type="fig"}), confirming that these genes, regardless of the categories to which they are assigned, are associated with COPD. Most of the input DEGs were inter-connected in a large network and the functional terms of each clustered subgroup in the network were consistent with the functions mentioned above, suggesting that these DEGs may participate in the pathogenic pathway leading to COPD. The integration of an additional source of functional information about these DEGs, i.e., previously known COPD-associated genes, including *EGFR*, *PTGS2*, *IL6*, *CXCR1* and *CXCR2*, obtained from DisGeNET (see the Methods), into this Cytoscape-generated diagram, as depicted by the gene symbols inside the bigger circles, provided strong support for the hypothesis that these DEGs potentially represent very reliable gene sets for deciphering the molecular etiology of COPD.

Statistically significant miRNA-DEG pairs and eQTL-DEG pairs
------------------------------------------------------------

We next attempted to further characterize the 237 common NC-DEGs by integrating them with other multi-omics data. Previously, [@b21-ksmcb-42-333] reported a total of 45 miRNAs to be differentially expressed in COPD patients (i.e., DE-miRNAs) compared with normal controls. It is hypothesized that the alteration of miRNA expression could lead to alterations in target gene expression, considering that miRNAs are well-established regulators of gene expression. Consequently, we searched the 237 common NC-DEGs for genes predicted to be targeted by these 45 DE-miRNAs by examining the intersection of these DEGs with previously known miRNA-target mRNA pairs (see the Methods). As a result, 43 of the 45 miRNAs were associated with a total of 4,786 mRNA targets. By overlapping the 237 DEGs with the 4,786 miRNA targets, 66 NC-DEGs were identified ([Tables 1](#t1-ksmcb-42-333){ref-type="table"} and [Supplementary S4](#s4-ksmcb-42-333){ref-type="supplementary-material"}). Subsequently, a random permutation experiment was conducted to determine the extent of the significant enrichment of the 66 miRNA-DEG pairs among the 237 DEGs within the total of 4,786 genes. We confirmed that the 66 genes linked to the DE-miRNAs were impossible to obtain by chance, indicating that the 66 DEGs were significantly enriched through an interaction with DE-miRNAs ([Fig. 5A](#f5-ksmcb-42-333){ref-type="fig"}).

Another mechanism of gene expression alteration is genetic mutations that occur in *cis*-acting regulatory elements, such as promoters and enhancers. The genetic changes associated with gene expression have been studied by the identification of eQTLs. We acquired this eQTL information from the GTEx database (see Methods) to investigate whether the NC-DEGs are affected by any eQTL. Ninety-six common NC-DEGs mapped onto the locations of eQTL SNPs within their regulatory regions ([Tables 1](#t1-ksmcb-42-333){ref-type="table"} and [Supplementary S5](#s5-ksmcb-42-333){ref-type="supplementary-material"}). A similar random permutation experiment to the analysis of the DEG-miRNA pairs was applied. During each random iteration repeated 1,000 times, we estimated the number of DEGs coupled with eQTLs of the 237 randomly selected genes among the total of 11,297 lung eQTLs ([Fig. 5B](#f5-ksmcb-42-333){ref-type="fig"}). The 96 eQTL-DEG pairs we observed were significantly enriched and not expected by random chance ([Fig. 5B](#f5-ksmcb-42-333){ref-type="fig"}). Consistently, 91% (87/96) of those SNPs were located in regulatory regions, such as TFBSs, enhancers, promoters, or DHSs ([Supplementary Table S5](#s5-ksmcb-42-333){ref-type="supplementary-material"}).

Relationships between GO functional classes and regulatory alterations
----------------------------------------------------------------------

We then examined whether a general pattern occurred in the mechanism of regulatory alterations, mediated either by miRNAs or by eQTLs, in functional categories into which the common NC-DEGs were assigned. Two groups of DEGs, i.e., DEGs targeted by the 45 DE-miRNAs and DEGs mapped to eQTLs, were overlapped, resulting in three categories of DEGs: genes whose expression was altered only by DE-miRNAs (designated 'miRNA-specific'), genes whose expression was altered only by regulatory mutations (designated 'eQTL-specific'), and whose expression was altered by both mechanisms (designated 'both'). As shown in [Table 1](#t1-ksmcb-42-333){ref-type="table"}, only 20 NC-DEGs, including *EGFR*, *FASTK*, and *HIPK3*, were subject to regulation by both DE-miRNAs and eQTLs, and the functional GO terms of these NC-DEGs were 'apoptosis' or 'cell proliferation'. Forty-six genes, including *IL6*, *THBS1* and *HIPK2*, were 'miRNA-specific' and were grouped into 'cell proliferation' or 'cell adhesion'. The remaining 76 genes, including *ETFB*, *MMRN1* and *MRPL41*, were 'eQTL-specific' and were involved in mitochondrial functions, such as 'respiratory electron transport chain' or 'inflammatory response'. Interestingly, some genes, such as those associated with the 'respiratory electron transport chain', which are genes that are likely related to oxidative stress, were generally altered by regulatory genetic mutations rather than miRNA-mediated regulatory pathways.

Validating the alterations in the expression of selected genes in the mouse COPD models
---------------------------------------------------------------------------------------

[Supplementary Table S5](#s5-ksmcb-42-333){ref-type="supplementary-material"} summarizes our integration of COPD-related multi-omics data, from which we confirmed several novel genes, such as *STRA13* and *FGG*, as well as well-known COPD-related genes, such as *MIF* and *SOD2*. We decided to validate some of these DEGs using qRT-PCR. Since no human COPD samples were available, we tried to validate the expression of these genes in two different mouse COPD models, elastase-induced COPD (El-COPD) and smoking-induced COPD (Sm-COPD) (see Methods). Genes were selected by referencing [Supplementary Table S5](#s5-ksmcb-42-333){ref-type="supplementary-material"} and previous literature. For instance, the *MIF* gene was selected because it contained an eQTL SNP, to which several TFBSs were mapped and linked to the DE-miRNA, and studies have implicated this gene in COPD ([@b40-ksmcb-42-333]; [@b44-ksmcb-42-333]). The mouse models represented models of emphysema (i.e., one of the key symptoms of COPD) rather than exact models of human COPD. Nevertheless, the expression of six of the seven selected genes was confirmed to be altered in these mouse models ([Fig. 6](#f6-ksmcb-42-333){ref-type="fig"}). *Mif* and *Fastk* were specifically downregulated in EI-COPD, whereas *Ndufa7*, *Stra13 and Fgg* were specifically downregulated in Sm-COPD. Interestingly, the expression of the *Stx8* gene was downregulated in both models.

DISCUSSION
==========

Here, we identified genes that were significantly altered by COPD using samples previously published by [@b23-ksmcb-42-333]. We not only confirmed the previous finding, showing the perturbation in the gene expression of inflammatory genes and mitochondrial genes, but also revealed a novel aspect regarding the changes in putative regulatory regions that might affect changes in COPD-DEG expression.

A problem confronted by Kim et al. in their study ([@b23-ksmcb-42-333]) and by us in the present study was that all COPD samples were accompanied by lung cancers, either AC or SC. However, a substantial difference between the study by [@b23-ksmcb-42-333] and our present study is the strategy used to identify DEGs; we attempted to remove the bias driven by lung cancers in patients with COPD by detecting COPD-DEGs. Another difference was the recognition of an 'intermediate' group named group 'I', i.e., patients who cannot be classified as COPD or non-COPD by gene expression patterns alone. We observed few differences in gene expression levels between the 'N' and 'I' groups and between the 'I' and 'C' groups, and the FEV1/FVC ratio of group 'I' was scattered from low to high, indicating that COPD and non-COPD samples were likely intermingled within group 'I'. In other words, the clinical diagnosis of patients in group 'I' as either COPD or normal might have been inaccurate, potentially leading to the identification of less reliable COPD-DEGs if group 'I' samples were included in the datasets. We postulate that the exclusion of samples from group 'I' and the collection of NC-DEGs helped us unambiguously identify reliable COPD-DEGs. In fact, the subsequent analyses performed after DEG identification, including the GO analysis and functional interaction network analysis, confirmed the previous findings from COPD-driven transcriptome analyses, as the expression of inflammatory genes and apoptosis genes was upregulated, and the expression of oxidation-reduction genes was downregulated. A third difference exists with regard to our effort to integrate DEGs with various omics datasets to investigate a mechanistic question underlying the expression alteration occurring in COPD. The integration of multi-omics data, including GDA, eQTLs, and miRNAs, provided us an opportunity to link changes in upstream regulatory regions and changes in downstream gene expression, through which we identified some common pathways involved in the development of COPD, regardless of co-occurring cancer types. Additionally, different functional classes of genes were altered by different lung cancer backgrounds or by the upregulation or downregulation of genes.

Finally, we further validated alterations in the expression of some selected genes in the two mouse COPD model systems, in which *Stx8* in particularly emerged. Interestingly, the downregulation of S*tx8* in COPD was consistent not only with the finding in the human samples but also between the two mouse model systems ([Figs. 6A and 6B](#f6-ksmcb-42-333){ref-type="fig"}), which provides the insight that some molecular etiologies may be shared between different species and even different environmental causes. *Stx8* belongs to the 'syntaxin' family, i.e., gene groups of membrane proteins participating in exocytosis, a GO term in the molecular functional category of 'chloride channel inhibitor activity'. This gene function related to chloride channel activity leads to the topic of cystic fibrosis, a well-known genetic disease caused by mutation of the chloride channel encoded by the *CFTR* gene. In future studies, it will be interesting to examine whether the downregulation of the *Stx8* gene can be a direct cause of COPD and, if so, how that effect might occur at the level of molecular mechanisms.

We think that our present study will contribute to understanding the molecular etiology of COPD coupled with lung cancers and to identifying diagnostic markers of COPD.
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![Overall schematic of the workflow\
AC: adenocarcinoma; SC: squamous cell carcinoma; Q: FDR-adjusted *p*-value; FC: fold change; N: normal group; I: intermediate group; C: COPD group.](ksmcb-42-333f1){#f1-ksmcb-42-333}

![Heatmap and PCA analysis of DEGs and a comparison of clinical characteristics of N, I and C samples in the AC and SC groups\
DEGs were isolated separately for AC and SC, as displayed. Left panels (A and D) show the results of the heatmap analysis accompanied by the unsupervised clustering of samples using the 150 AC-DEGs and 58 SC-DEGs. Dendrograms showing distances between the samples, generally displayed at the top of heatmaps, are omitted, and colored bars are used instead to represent normal samples (colored cyan blue) and COPD samples (colored red). The middle panels (B and E) show the results of the PCA accompanied by *k*-means clustering (*k* = 3). Each dot represents one patient sample; normal, intermediate, and COPD samples are colored cyan, gray, and red, respectively. Some outlier samples that were clinically diagnosed as normal but showed similar gene expression to COPD, or vice versa, as indicated with colored cyan blue and red circles, respectively. These outliers were excluded from further analyses. The right panels (C and F) show boxplots of the FEV1/FVC ratios for N, I and C samples. The red dotted lines represent the median value of N. Significance was tested using Student's *t* -test (\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001).](ksmcb-42-333f2){#f2-ksmcb-42-333}

![Heatmaps created with NC-DEGs\
NC-DEGs were isolated for AC- and SC-COPD samples, as described in the main text. Heatmap analyses coupled with unsupervised clustering, as described in [Fig. 2](#f2-ksmcb-42-333){ref-type="fig"}, were conducted for AC and SC, respectively (top panels). By examining the intersection of the DEG results from the AC- and SC-COPD groups, we identified commonly altered NC-DEGs named common NC-DEGs (see the main text). Heatmap analyses coupled with unsupervised clustering were performed on the common NC-DEGs and all (AC plus SC) samples (bottom panels).](ksmcb-42-333f3){#f3-ksmcb-42-333}

![GO and network analysis of the common NC-DEGs\
(A) GO analysis of up- or downregulated 'AC-specific', 'SC-specific', and 'common' DEGs, as described in the main text. Red and blue represent GO functional terms for up- and downregulated genes, respectively. The top five GO terms selected based on the -log~10~(*p*-value) are depicted in bar graphs and are presented on the right side of the bars. (B) A functional interaction network was created with the Reactome FI plugin of the Cytoscape tool (see the Methods). Each gene in each circle is linked by functional interaction; red outlines: upregulated, blue outlines: downregulated, black symbols inside blank balls: common DEGs, yellow symbols inside gray balls: AC-specific DEGs, white symbols inside black balls: SC-specific DEGs. The larger sized circle indicates known COPD-associated genes.](ksmcb-42-333f4){#f4-ksmcb-42-333}

![Permutation test of miRNA-DEG pairs and eQTL-DEG pairs\
A random permutation experiment was conducted to the extent of the significance of the number of miRNA-DEGs, 66 genes (A), and the number of eQTL-DEGs, 96 genes (B), by comparing the values with random chance. A. During each random iteration that was repeated at least 1,000 times, the number of DEGs among the 237 randomly selected genes from the total of 4,786 genes determined to be DE-miRNA target genes was estimated and plotted against the observed number, i.e., 66. B. During each random iteration that was repeated at 1,000 times, the number of DEGs among the 237 randomly selected genes from the total of 11,297 genes with lung eQTLs retrieved from GTEx database (see the Methods) was estimated and plotted against the observed number, i.e., 96.](ksmcb-42-333f5){#f5-ksmcb-42-333}

![Functional validation of selected DEGs using two COPD mouse model systems\
Seven genes were chosen to be validated by RT-qPCR in the two mouse COPD model systems (see Methods). A. RT-qPCR results from a mouse model of elastase-induced COPD; five El-COPD mice and five C57BL/6J mice were compared. B. RT-qPCR results from a mouse model of smoking-induced COPD; three Sm-COPD mice and three C57BL/6J mice were compared. Significance was tested by Student's *t*-test (\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001).](ksmcb-42-333f6){#f6-ksmcb-42-333}

###### 

Results of the GO analysis

  Category (n)                                                                             Gene Ontology                                             *p*-value
  ---------------------------------------------------------------------------------------- --------------------------------------------------------- -----------
  miRNA specific (46)                                                                      positive regulation of smooth muscle cell proliferation   4.26E-07
  positive regulation of transcription from RNA polymerase II promoter                     2.61E-05                                                  
  positive regulation of cell proliferation                                                1.64E-04                                                  
  cellular response to tumor necrosis factor                                               2.79E-03                                                  
  cell adhesion                                                                            6.11E-03                                                  
                                                                                                                                                     
  Both (20)                                                                                positive regulation of ERK1 and ERK2 cascade              9.54E-04
  negative regulation of apoptotic process                                                 1.49E-03                                                  
  positive regulation of fibroblast proliferation                                          1.68E-03                                                  
  positive regulation of MAP kinase activity                                               2.00E-03                                                  
  leukocyte migration                                                                      8.26E-03                                                  
                                                                                                                                                     
  eQTL specific (76)                                                                       respiratory electron transport chain                      2.00E-03
  lymphocyte homeostasis                                                                   1.66E-02                                                  
  positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage   1.98E-02                                                  
  inflammatory response                                                                    3.74E-02                                                  
  protein phosphorylation                                                                  6.53E-02                                                  
